Dataset opportunity
G 21 — 医疗影像数据集机会
G 21 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
42.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医疗诊断人工智能市场 = 2023 年为 16.4 亿美元，复合年增长率为 26.40%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
高度关注生物材料和医疗设备的研发
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（需审查个人身份信息）
Buyer persona
医疗人工智能与诊断影像公司
G 21 持有一份专门的医疗影像数据集，该数据集来自其骨科和脊柱生物材料的临床试验和上市后监测。该集合包括 X 射线、CT 和 MRI 等影像模态，并附有相应的病历、专有材料测试数据和监管文件，使其非常适合训练和验证用于评估植入物性能和患者预后的诊断人工智能模型。
该数据定位于全球医疗诊断人工智能市场，该市场在 2023 年的估值为16.4 亿美元，预计将以 26.40% 的复合年增长率增长。[6] 虽然由于严格的 GDPR 和医疗器械法规（CE/ISO）的限制，访问权限复杂，但这确保了数据集的高质量和稀有性。这种复杂性使得该数据成为旨在快速增长的市场中开发经过认证的下一代诊断工具的实体的独特宝贵资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床试验数据受严格的医疗保健法规和 GDPR 的约束；生物材料的专有化学和机械测试数据；访问需要应对医疗器械认证限制（CE/ISO）· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 G 21 拥有关于骨科骨水泥的专有端到端数据集，涵盖从专有研发测试到上市后监测。该数据集独特地结合了临床研究图像与机械测试数据和监管文件，创建了一个全面的资产。对于开发诊断人工智能的公司来说，这些数据对于训练算法以评估设备安全性和有效性至关重要，这是蓬勃发展的医疗诊断人工智能市场中的关键差异化因素，该市场正以每年超过 26% 的速度增长。
See dimension details ↓- Dataset Specificity90
主导的“病历”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求极高，这得益于医疗诊断人工智能市场以 26.40% 的来源复合年增长率快速扩张。[6]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit42
⚠ 审查 — 该公司制造和销售骨水泥和骨科垫片等实体医疗设备；它不拥有其产品使用产生的临床或运营数据，因此是一个糟糕的目标。问题：该公司的核心业务是制造和销售医疗技术产品，而不是提供作为副产品生成数据的服务。[2, 3, 7, 9]；有价值的数据（临床结果、患者数据、影像）由使用 G21 产品的医院和外科医生生成并拥有，而不是由 G21 本身拥有；该公司是一家产品供应商，而不是 ICP 定义的休眠运营数据持有者。
- Deep Qualification90
✓ 通过 — G21 是一个强大的数据持有者候选者。它开发和制造骨科生物材料，使得收集临床试验和强制性上市后监测的医疗影像数据具有高度可行性。最近被一家私募股权公司多数收购以加速研发和扩张，这是一个强烈的触发因素。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据指向了来自临床研究和上市后监测的医疗影像集合，这对于训练诊断人工智能以评估骨水泥的实际安全性和有效性至关重要。
Industrial data
这代表了骨科产品的机械和化学测试的专有时间序列数据，为预测材料性能和故障的人工智能模型提供了一个独特的地面真实数据集。
Regulatory records
这包括证明ISO 13485 合规性和CE 标记的监管文本文件，这验证了数据的商业级来源，并为寻求自身监管批准的任何人工智能解决方案提供了关键背景。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
G 21 Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics market = $1.64 billion in 2023, CAGR 26.40% (source: BlueWeave Consulting). Investment score 42.5/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Neocis — 医疗影像数据集机会
View opportunity →移动出行Quicargo — 移动和地理空间数据集商机
View opportunity →零售Jamesandjames — 事件流数据集机会
View opportunity →